Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study.

J Immunother Cancer · 2024 · PMC11535711 · PMID 39489541

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an expected trendno p-value reported

The primary end point of this study was disease control, so performance was evaluated using the DCR for each OncoPrism group, with an expected trend from lower DCR in the low group to higher DCR in the high group.

also in 179 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.